couter

000566.SZHainan Haiyao Co., Ltd.

Health CarePharmaceuticals
Oct 30, 2026 — Q3 2026 Earnings & Margin Performance
Chart by TradingView

The schedule

  • Fri30Oct
  • Wed20Jan

    Potential API export impacts evaluated from a $3.50 base as President Trump's administration escalates scrutiny on Chinese pharmaceutical supply chains.

  • Wed28Apr

Resolved

  • Fri28Aug

    MIXED · $4.99 at outcome

    Price at outcome date was between bear floor ($4.10) and bull target ($5.30).

    Market evaluation of H1 2026 results, focusing on the company's ability to navigate severe leverage (debt of $2.6B vs $4.4M equity) with a baseline of $4.84.